Cancer treatments including traditional, new targeted kinase inhibitors and immunotherapies are associated with cardiovascular and metabolic adverse effects. Cardio-oncology is a relatively new discipline, aiming at finding an optimal balance between the efficacy of anticancer treatments and the management of their adverse cardiac effects. It includes the prevention, diagnosis, and treatment of these complications in cancer patients. Research in cardio-oncology also aims at elucidating the mechanisms involved in cardiotoxicity and cardioprotection, leading to the identification of novel targets for drug discovery. This section of Frontiers in Cardiovascular Medicine provides a high visibility platform for the publication of original research and expert reviews on the Cardiotoxicity with cancer therapy as it pertains to genomics, proteomics, and metabolomics.
In particular, this special issue mainly invites contributions that report on the following issues in cardio-oncology:
· Toxicity and cardioprotective signaling (e.g. epigenetic alterations, genomic instability, loss of proteostasis, mitochondrial functions, metabolic alterations)
· Induced pluripotent stem cells derived cardiomyocytes and vascular cells as a model for toxicity
· Robust preclinical models to determine cardiovascular toxicity (Shortcomings of current preclinical testing and correlation of the preclinical models with the clinic output)
· Cardioprotective drug discovery (development of new leads based on phenotypic screening or targeting a defined molecular target, drug repositioning)
· Modifiable and genetic risk factors for Cardiotoxicity, in particular as and how they relate to proteomic and metabolomic disturbances
· Clinical Biomarkers of cardiac toxicity (Clinical Studies on genomics, proteomics, metabolomics in cancer patients and correlation with Cardiotoxicity)
· Translational scope studies and reviews on how genomics, proteomics, and metabolomics could be integrated into clinical practice
· Studies and reviews on the use of large genomic, proteomic and metabolomic databases (“big data in cardio-oncology”)
· Prevention and treatment of cardiotoxicity
Cancer treatments including traditional, new targeted kinase inhibitors and immunotherapies are associated with cardiovascular and metabolic adverse effects. Cardio-oncology is a relatively new discipline, aiming at finding an optimal balance between the efficacy of anticancer treatments and the management of their adverse cardiac effects. It includes the prevention, diagnosis, and treatment of these complications in cancer patients. Research in cardio-oncology also aims at elucidating the mechanisms involved in cardiotoxicity and cardioprotection, leading to the identification of novel targets for drug discovery. This section of Frontiers in Cardiovascular Medicine provides a high visibility platform for the publication of original research and expert reviews on the Cardiotoxicity with cancer therapy as it pertains to genomics, proteomics, and metabolomics.
In particular, this special issue mainly invites contributions that report on the following issues in cardio-oncology:
· Toxicity and cardioprotective signaling (e.g. epigenetic alterations, genomic instability, loss of proteostasis, mitochondrial functions, metabolic alterations)
· Induced pluripotent stem cells derived cardiomyocytes and vascular cells as a model for toxicity
· Robust preclinical models to determine cardiovascular toxicity (Shortcomings of current preclinical testing and correlation of the preclinical models with the clinic output)
· Cardioprotective drug discovery (development of new leads based on phenotypic screening or targeting a defined molecular target, drug repositioning)
· Modifiable and genetic risk factors for Cardiotoxicity, in particular as and how they relate to proteomic and metabolomic disturbances
· Clinical Biomarkers of cardiac toxicity (Clinical Studies on genomics, proteomics, metabolomics in cancer patients and correlation with Cardiotoxicity)
· Translational scope studies and reviews on how genomics, proteomics, and metabolomics could be integrated into clinical practice
· Studies and reviews on the use of large genomic, proteomic and metabolomic databases (“big data in cardio-oncology”)
· Prevention and treatment of cardiotoxicity
